Apr 27, 2022 — 3 min read
First CE Mark for Lunit AI-powered pathology solution
Lunit to focus on launching ‘Lunit SCOPE PD-L1’ in Europe within the second half of 2022
Lunit, a leading medical AI provider, today announced it has received the CE-IVDD Mark for ‘Lunit SCOPE PD-L1 TPS’, an AI-based PD-L1 tumor proportion score (TPS) analyzer. While Lunit’s INSIGHT product scored the CE Mark in 2019 and 2020, this is the first time for a Lunit SCOPE product to receive European approval.
Lunit SCOPE PD-L1 is an AI solution that performs PD-L1 TPS classification that enhances objective and accurate analysis compared to traditional method.
The product, trained with more than 1,000,000 cancer cell images, precisely analyzes PD-L1 biomarker expression and classifies PD-L1 TPS into three groups: 50% or more, 1-49%, and 0%. This digitized assistance substantially supports pathologists in diagnosing the status with high accuracy and consistency in analysis performance.
“This CE Mark certification is a meaningful milestone,” said Brandon Suh, CEO of Lunit. “It demonstrates the expansion of Lunit’s offerings to the cancer biopsy field beyond the scope of medical image analysis. As our AI technology gains reliability and recognition, we will do our utmost to pioneer the overseas market.”
Lunit is working on launching Lunit SCOPE PD-L1 in Europe within the second half of 2022, paving the way for deployment and use in European pathology practices.
Lunit wins Tumor Proliferation Assessment Challenge (TUPAC) 2016
Lunit to unveil data-driven imaging biomarker at RSNA 2016
Lunit to showcase AI-powered products at USCAP 2017
Lunit INSIGHT: The First-ever, Real-time Imaging AI Analytics on the Web
Uncertainty and Deep Learning
Lunit Returns to RSNA with Real-time Imaging Platform, Featuring Cloud-based A
Lunit Unveils “Lunit INSIGHT,” A New Real-time Imaging AI Platform on the Web at RSNA 2017
Lunit INSIGHT: Q&A with Brandon B. Suh, Chief Medical Officer at Lunit
ANNOUNCING: BRANDON SUH, OUR NEW CEO
Lunit preps Korean IPO led by NH Investment Bank
Media Advisory: Lunit at RSNA 2018
Lunit Partners with Fujifilm and Salud Digna to Provide Medical AI Solution in Mexico
Lunit announces new members in its advisory board: Dr. Eliot Siegel, Dr. Linda Moy, and Dr. Khan Siddiqui
Lunit to Introduce Medical AI Solutions at GTC 2019
Lunit to Present Abstracts on AI-powered Precision Pathology at 2019 AACR Annual Meeting
Lunit to Present Findings on the Predictive Power of AI Biomarker for Lung Cancer Immunotherapy at ASCO 2019
Lunit Receives Korea MFDS Approval for its AI Solution for Breast Cancer, Lunit INSIGHT MMG
Lunit Named to the 2019 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
Lunit at RSNA 2019
Lunit Announces its First CE Mark for AI-Powered Chest X-ray Analysis Software, Lunit INSIGHT CXR
Lunit Secures $26M in Series C Funding Round, Led by Asian Investors
Renowned Oncologist Dr. Tony Mok Joins Lunit Advisory Board
Lunit to Present Findings on the Predictive Power of AI-based Analysis of Immune Phenotype at ASCO 2020
Lunit Awarded as Technology Pioneer by World Economic Forum
Lunit at ECR 2020: Providing Virtual Exhibition and Online Presentations
Lunit Named to the 2020 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
Emergent Connect Partners with Lunit to Provide Cloud Based AI Solutions
AI has Added Value in Insurance Underwriting Process, Recent Pilot Project Between Lunit and Cathay Financial Innovation Lab Reveals
RSNA 2020--Lunit Collaborates with Global Giants in Presenting its AI Solution at Virtual Booths of GE Healthcare, FujiFilm, and Sectra
Lunit Expands Collaboration with GE Healthcare to Advance AI Adoption across Healthcare Industry
What do medical studies say about AI for COVID-19 management?
What do the medical journals say about AI-powered mammography?
Research Using Lunit Demo Website
Lunit Presents AI-powered Pathologic Classification of Immune Phenotype that Predicts Response to Immunotherapy at USCAP 2021
What do the medical journals say about AI-powered chest x-ray interpretation?
Join our webinar with Dr. Fredrik Strand
From retrospective to prospective trials of AI in breast cancer screening
AACR 2021 - Lunit Presents Abstracts Demonstrating the Potential of its AI Biomarker in Cancer Treatment
Will AI Identify Breast Cancer Better Than Radiologists in Actual Clinical Screening?
Case of the Month | Where Is Breast Cancer?
AI-based Analysis of Cancer Tissue Predicts Response to Immunotherapy--Findings to Be Presented at ASCO 2021
Clinical Application of Lunit AI For Chest Radiography and Mammography to Be Presented at AOCR 2021
Lunit Secures $26M Investment from Guardant Health in a Strategic Funding Round
A Multi-reader Study Finds Unnecessary CT Exams Can Be Reduced by 30% When Analyzing Chest Radiographs with AI
Fujifilm Introduces its AI-powered Product for Chest X-ray in Japan, in Collaboration with Lunit
Lunit Collaborates with Intel to Provide AI Solutions to CPU-Based Customers in Need of Effective X-ray Diagnosis
Lunit AI Applied to Clinical Trial for Drug Development for the First Time--Findings Presented at ESMO 2021
Case of the Month (Chest x-ray)
COVID Global User Testimonials
Where is Cancer?
Breast Cancer Awareness Month — Ambassador Messages
TimeSformer: Is Space-Time Attention All You Need for Video Understanding?
Evaluation curves for object detection algorithms in medical images
Lunit to Participate in RSNA 2021, Presenting its New AI Solutions for Digital Breast Tomosynthesis and Chest CT
RadLink, Singapore’s Leading Imaging Center, Adapts Lunit AI to Analyze Chest X-rays and Mammograms
Lunit Expands Team with Multiple Industry Leaders to Accelerate its Business Growth
Lunit Presents Studies at SITC 2021, Highlighting the Effectiveness of AI in Predicting Response to Immunotherapy in a Clinical Trial Setting
Lunit Gets FDA Nod for AI-based Chest X-ray Triage Solution, Developed for Sorting of Emergency Cases
Lunit's AI Software for Breast Cancer Detection, Lunit INSIGHT MMG, Wins FDA Clearance
Research Backs Clinical Efficacy of Lunit's Radiology AI Products; Abstracts to be Presented at RSNA 2021
Medical AI Provider Lunit Raises $61M in Funding Round Led By Major Global Healthcare Investors
Lunit Named to the 2021 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
Lunit Obtains MDSAP Certificate, Granted Fast-Track Regulatory Process in Major Countries
Lunit to Showcase Chest and Breast Radiology AI in Arab Health 2022
Baheya Foundation, Egypt’s Premier Destination for Breast Cancer, Adopts Lunit AI to Enhance Early Screening
Breakthrough Study Validates Artificial Intelligence as a Novel Biomarker in Predicting Immunotherapy Response - Published in Journal of Clinical Oncology
Lunit AI Demonstrates Accuracy in Practical Assessment of Cancer Tissue-Findings to Be Presented at USCAP 2022
Case of the Month (Chest x-ray) - Tuberculosis Case
New Studies at AACR 2022 Highlight Lunit SCOPE’s Immune Phenotyping Capabilities
Medical AI Startup Lunit gets Preliminary Approval to go Public on KOSDAQ
Lunit to Present 11 Abstracts at the 2022 ASCO Annual Meeting
Lunit AI Biomarker PD-L1 Demonstrates Clinical Efficacy as Diagnostic Aid in Cancer Treatment–Published in the European Journal of Cancer
New Studies at ASCO 2022 Validate Effectiveness of Lunit AI as Diagnostic Aid in Cancer Treatment